Roche allies with biotech incubator; WHO casts doubt on Ebola pipeline;

@FierceBiotech: IPOs: $FGEN comes up big while $NDRM limps out of the gate. Story | Follow @FierceBiotech

@JohnCFierce: Puma drug neratinib flunks PFS, ORR endpoints. Article | Follow @JohnCFierce

@DamianFierce: $GERN rides again as $JNJ partners up on imetelstat for up to $900M. Release | Follow @DamianFierce

> Roche ($RHHBY) has signed a deal with Cambridge, MA, biotech incubator LabCentral to kick in research technology and funding in support of the outfit's budding startups. More

> The World Health Organization, combing through data on the more than 120 identified potential Ebola treatments, noted that while many have shown promise, none is a sure-fire answer for the epidemic. News

Medical Device News

@FierceMedDev: Glooko merges tech data to avoid activity-triggered hypoglycemic events. More | Follow @FierceMedDev

@VarunSaxena2: Philips, Duke to collaborate on infant temperature monitoring using InnerSense probe. Article | Follow @VarunSaxena2

@EmilyWFierce: $BSX ordered to pay $26.7M in one of first federal trials over vaginal mesh devices. Story | Follow @EmilyWFierce

> Monteris nabs $30M to grow its less invasive neurosurgery tech. Story

> St. Jude 'looking' to expand production and services operations in Malaysia. More

Pharma News

@FiercePharma: Top-read special report: The top 10 #pharma companies by 2013 revenue. Report | Follow @FiercePharma

@EricPFierce: ICYMI: Cadilia gets slapped with #FDA warning for not following up on complaints about stinking APIs. More | Follow @EricPFierce

@CarlyHFierce: Why are M&A hedge funds gun shy? Blame AbbVie for killing its Shire deal. Story | Follow @CarlyHFierce

> Another Pfizer run at AZ? Unlikely, Reuters' sources say. But keep an eye on Actavis. More

> EMA director Rasi sidelined by complaint from colleague who wanted his job. Article

> New biologics plant for Bristol-Myers promises 400 jobs for Ireland. News

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.